Regeneron Pharmaceuticals, Inc. (REGN) Q2 2013 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.1%

Regeneron's strong EPS performance indicates better-than-expected profitability, but the stock fell by 6.1% in reaction. Investors may be concerned about the lack of revenue details and future guidance. The cautious tone from management suggests that while they are optimistic, there are challenges ahead that could impact growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.73	N/A	+100.46%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of optimism regarding future product developments. However, they acknowledged the competitive landscape.

Management highlighted ongoing research and development efforts.

They expressed confidence in their pipeline despite market challenges.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.1%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.1%

Key numbers

Management commentary